Nuvectra Corporation Appoints Chief Technology Officer

Nuvectra Corporation, a neurostimulation medical device company, has appointed Ben Tranchina as chief technology officer (CTO). Tranchina has over 25 years of industry experience and most relevantly served as vice president of Product Development at St. Jude Medical Inc., where he led the development of the company’s neuromodulation portfolio, following his time at Advanced Neuromodulation Systems Inc.
 
Tranchina will replace the company’s current CTO, Dr. Norbert Kaula, who announced his intention to resign to pursue other interests.
 
Scott Drees, CEO, commented, “I am excited to welcome Ben to the Nuvectra team, and to work closely with him again following our years together at Advanced Neuromodulation Systems Inc. and St. Jude Medical. We believe that his extensive neuromodulation experience will be highly relevant as we advance our platform technology. We anticipate a seamless transition and would like to take the opportunity to thank Dr. Norbert Kaula for his accomplishments through his nine years of service to the company, and wish him continued success in his future endeavors.”
 
Tranchina has more than 25 years of experience in technology business leadership for early-stage and multinational commercial companies, and approximately 30 issued or pending patents relevant to neuromodulation. Most importantly, Tranchina served in various leadership roles for nine years at Advanced Neuromodulation Systems Inc. and St. Jude Medical, where he led the development of nine first-to-market products.
 
Most recently, Tranchina was the CTO of Neurotechnology Innovations Translator (NIT) LLC, a privately held company which develops and commercializes neurotechnology solutions. During his tenure at NIT, he also served as CEO for NIT portfolio company, Veressa Medical, where he led development of an innovative peripheral nerve stimulation system for the treatment of pelvic floor dysfunction and peripheral pain.

Tranchina has both a bachelor’s and Master’s degrees in electrical engineering from the University of Texas at Dallas, specializing in microelectronic circuits and systems.
 
Nuvectra is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita Spinal Cord Stimulation (SCS) System is its first commercial offering and is CE marked and U.S. Food and Drug Administration-approved for the treatment of chronic intractable pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, its NeuroNexus subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market.